MZEI – Canada Leads the Way and Dr. Shannon has Led Canadian Medicine in this Field

Michael E. Shannon, M.A.,M.Sc.,M.D.
Board Member & Director of Medical Affairs at MZEI

Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years. He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada.

Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health.

First, Canada is hugely important in understanding the statistics involved in hospital infections.  Why?  In the U.S. these are kept quiet.  Covered up.  Not reported.  Not that Canadian hospitals do not sometimes fudge their data — but in the United States the hospital industry has done a super job of covering up the SUPER BUGS that reside within their domain and end up killing patients — ones who were not that sick to begin with.

Ontario hospitals must post any outbreaks, along with their monthly infection rates, online in a searchable database.

People want, need, and have a right to transparency and in the United States the Federal Government and State Legislatures are saying ENOUGH.  We want data and statistics, too.

In Canada reducing the number of infections patients pick up is part of a national safety push.  The increasing prevalence of drug-resistant infections has made hospitals a reservoir for bacteria and transmission of disease.  The U.S. now wants this information as well.

The site, www.myhospitalcare.ca, has been established by the Ontario Hospital Association, a group representing the 155 hospital corporations in Ontario.  It uses 39 health indicators, such as C. difficile infection rates and hospital death rates, to inform the public about their hospital.  The myhospitalcare.ca website blends data from a variety of sources, such as the Ontario health ministry and the Canadian Institute for Health Information, and then presents the indicators experts believe are of the greatest interest to the public.

Dr. Shannon comes to this project with a full understanding of the dynamics of reporting hospital infections.  The reporting will create demand for MZEI’s product.

During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada.

He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.

In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product.

He then accepted a special assignment with the Canadian Federal Government Auditor General’s office to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004.

Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor.  He directed the rebuilding of the Emergency Medical Response Capacity for Canada.

Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS.

He was responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.

Canada is leading the way in this field and Dr. Shannon is leading Canada.

Contact:
Medizone International, Inc. (OTC: MZEI)
144 Buena Vista
P.O. Box 742
Stinson Beach, CA 94970
Web: http://www.medizoneint.com
Telephone: 415-868-0300
Fax: 415-868-2344
Investor Relations 800-953-3350
E-mail: operations@medizoneint.com

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 200,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This blog contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to,the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.